BACKGROUND: In the pre-antiretroviral therapy (ART) era, markers of increased disease severity during an acute opportunistic infection (OI) were associated with mortality. Even with ART, mortality remains high during the first year after an OI in persons with advanced HIV infection, but it is unclear whether previous predictors of mortality remain valid in the current era. OBJECTIVE: To determine clinical and immunological predictors of death after an OI. METHODS: We used clinical data and stored plasma from ACTG A5164, a multicenter study evaluating the optimal timing of ART during a nontuberculous OI. We developed Cox models evaluating associations between clinical parameters and plasma marker levels at entry and time to death over the first 48 weeks after the diagnosis of OI. We developed multivariable models incorporating only clinical parameters, only plasma marker levels, or both. RESULTS: The median CD4+ T-cell count in study participants at baseline was 29 cells/µL. Sixty-four percent of subjects had Pneumocystis jirovecii pneumonia (PCP). Twenty-three of 282 (8.2%) subjects died. In univariate analyses, entry mycobacterial infection, OI number, hospitalization, low albumin, low hemoglobin, lower CD4, and higher IL-8 and sTNFrII levels and lower IL-17 levels were associated with mortality. In the combined model using both clinical and immunologic parameters, the presence of an entry mycobacterial infection and higher sTNFrII levels were significantly associated with death. CONCLUSIONS: In the ART era, clinical risk factors for death previously identified in the pre-ART era remain predictive. Additionally, activation of the innate immune system is associated with an increased risk of death following an acute OI.
BACKGROUND: In the pre-antiretroviral therapy (ART) era, markers of increased disease severity during an acute opportunistic infection (OI) were associated with mortality. Even with ART, mortality remains high during the first year after an OI in persons with advanced HIV infection, but it is unclear whether previous predictors of mortality remain valid in the current era. OBJECTIVE: To determine clinical and immunological predictors of death after an OI. METHODS: We used clinical data and stored plasma from ACTG A5164, a multicenter study evaluating the optimal timing of ART during a nontuberculous OI. We developed Cox models evaluating associations between clinical parameters and plasma marker levels at entry and time to death over the first 48 weeks after the diagnosis of OI. We developed multivariable models incorporating only clinical parameters, only plasma marker levels, or both. RESULTS: The median CD4+ T-cell count in study participants at baseline was 29 cells/µL. Sixty-four percent of subjects had Pneumocystis jirovecii pneumonia (PCP). Twenty-three of 282 (8.2%) subjects died. In univariate analyses, entry mycobacterial infection, OI number, hospitalization, low albumin, low hemoglobin, lower CD4, and higher IL-8 and sTNFrII levels and lower IL-17 levels were associated with mortality. In the combined model using both clinical and immunologic parameters, the presence of an entry mycobacterial infection and higher sTNFrII levels were significantly associated with death. CONCLUSIONS: In the ART era, clinical risk factors for death previously identified in the pre-ART era remain predictive. Additionally, activation of the innate immune system is associated with an increased risk of death following an acute OI.
Entities:
Keywords:
HIV infections/complications; mortality; opportunistic infections
Authors: Netanya G Sandler; Handan Wand; Annelys Roque; Matthew Law; Martha C Nason; Daniel E Nixon; Court Pedersen; Kiat Ruxrungtham; Sharon R Lewin; Sean Emery; James D Neaton; Jason M Brenchley; Steven G Deeks; Irini Sereti; Daniel C Douek Journal: J Infect Dis Date: 2011-01-20 Impact factor: 5.226
Authors: Bethan McDonald; Sikhulile Moyo; Lesego Gabaitiri; Simani Gaseitsiwe; Hermann Bussmann; John R Koethe; Rosemary Musonda; Joseph Makhema; Vladimir Novitsky; Richard G Marlink; C William Wester; Max Essex Journal: AIDS Res Hum Retroviruses Date: 2013-05-09 Impact factor: 2.205
Authors: F Fanjul; M Riveiro-Barciela; J Gonzalez; E Delgado; J Murillas; A Payeras Cifré; V Falcó; M Riera Journal: HIV Med Date: 2012-12-06 Impact factor: 3.180
Authors: Philip M Grant; Lauren Komarow; Michael M Lederman; Savita Pahwa; Andrew R Zolopa; Janet Andersen; David M Asmuth; Sridevi Devaraj; Richard B Pollard; Aaron Richterman; Sudheesh Kanthikeel; Irini Sereti Journal: J Infect Dis Date: 2012-09-21 Impact factor: 5.226
Authors: Alessandro Cozzi-Lepri; Martyn A French; John Baxter; Pablo Okhuysen; Montserrat Plana; Jacqueline Neuhaus; Alan Landay Journal: AIDS Date: 2011-06-01 Impact factor: 4.177
Authors: Bruno Bezerril Andrade; Katherine Huppler Hullsiek; David R Boulware; Adam Rupert; Martyn A French; Kiat Ruxrungtham; Marisa Luisa Montes; Huw Price; Pablo Barreiro; Jennifer Audsley; Alan Sher; Sharon R Lewin; Irini Sereti Journal: J Infect Dis Date: 2013-01-18 Impact factor: 5.226
Authors: Maura Manion; Bruno B Andrade; Rebecca DerSimonian; Wenjuan Gu; Adam Rupert; Laura W Musselwhite; Juan G Sierra-Madero; Pablo F Belaunzaran-Zamudio; Ian Sanne; Michael M Lederman; Irini Sereti Journal: J Virus Erad Date: 2017-01-01
Authors: S Camon; C Quiros; N Saubi; A Moreno; M A Marcos; Y Eto; S Rofael; E Monclus; J Brown; T D McHugh; J Mallolas; R Perello Journal: BMC Infect Dis Date: 2018-04-19 Impact factor: 3.090